AI TRENDS | Eli Lilly Plans FDA Submission for Retatrutide Biologics License Application in Q1 2027
2026-07-23 10:49:26
According to Jin10, Eli Lilly (LLY.N) plans to submit a biologics license application for Retatrutide to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Noah Holdings CIO Says AI Capex Guidance May Not Lift Stocks
